Moleculin Biotech (MBRX) Expected to Announce Quarterly Earnings on Friday

Moleculin Biotech (NASDAQ:MBRX) is expected to be issuing its Q3 2025 results before the market opens on Friday, November 14th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 19, 2025 at 4:00 PM ET.

Moleculin Biotech (NASDAQ:MBRX) last announced its earnings results on Tuesday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, analysts expect Moleculin Biotech to post $-8 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Moleculin Biotech Stock Performance

Moleculin Biotech stock opened at $0.48 on Wednesday. The company’s 50 day simple moving average is $0.46 and its 200-day simple moving average is $0.61. Moleculin Biotech has a 1 year low of $0.25 and a 1 year high of $3.65. The company has a market capitalization of $23.71 million, a price-to-earnings ratio of -0.15 and a beta of 1.57.

Wall Street Analyst Weigh In

MBRX has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Moleculin Biotech in a research report on Wednesday, September 10th. Wall Street Zen cut Moleculin Biotech to a “strong sell” rating in a research note on Friday, October 3rd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Moleculin Biotech currently has an average rating of “Hold” and a consensus target price of $4.00.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.